To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

In today’s volatile political climate, Gen Zers are increasingly concerned about the future of their sexual rights. Emerging ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for ... Centers for Disease Control (CDC) will have to sign off on Abvrysvo's use in the wider age group.

GSK plc (LSE/NYSE: GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy ...

Arexvy shows 62.9% efficacy against RSV-LRTD over three seasons in adults aged 60 and older. The vaccine demonstrates 67.4% efficacy against severe RSV-LRTD, with consistent safety data. Arexvy is ...

RSV-A nAbs: SCB-1019 induced GMTs in RSV-A nAbs of approximately 30,500 IU/mL, compared to approximately 26,700 IU/mL for AREXVY and approximately 3,300 IU/mL for placebo at Day 28. RSV-B nAbs: ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy ... 9 has evaporated, in a sign of lingering concerns about ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...

RSV-A nAbs: SCB-1019 induced GMTs in RSV-A nAbs of approximately 30,500 IU/mL, compared to approximately 26,700 IU/mL for AREXVY and approximately 3,300 IU/mL for placebo at Day 28. RSV-B nAbs ...